Hematide™

Hematide™ is a synthetic, dimeric peptidic erythropoiesis-stimulating agent (ESA) covalently linked to PEG, which was the first product entering the clinic developed by Affymax.

Phase 1 clinic trials of Hematide™ was completed by 2005 and the hot results are now published in the journal Blood (108, 1830; 2006).

The results showed that all doses of Hematide™ were well tolerated, with safety profiles similar to those of placebo. And, Hematide™ administered as infrequently as once a month may result in a sustained elevation of Hgb levels.

Phase 2 trials of Hematide™ for the treatment of anemia associated with chronic kidney disease (CKD) and in anemic cancer patients undergoing chemotherapy (CIA) are now in progress.